By ICAA Sample Clauses

By ICAA. In its sole discretion, ICAA has the right to terminate this Agreement at any time during the Term without Cause. In the event ICAA terminates this Agreement without Cause, ICAA’s sole obligation shall be to pay Coach, as liquidated damages and not as a penalty, the amounts set forth below (the “ICAA Separation Payment”): Contract Year 1 60% of the amount equal to the remaining balance of Coach’s Guaranteed Compensation that would have been owed to Coach if Coach was fully performing Coach’s duties through the end of the Term. Contract Year 2 75% of the amount equal to the remaining balance of Coach’s Guaranteed Compensation that would have been owed to Coach if Coach was fully performing Coach’s duties through the end of the Term. Contract Year 3 35% of the amount equal to the remaining balance of Coach’s Guaranteed Compensation that would have been owed to Coach if Coach was fully performing Coach’s duties through the end of the Term. The applicable sum due to Coach shall be paid by ICAA over twelve (12) months in equal installments beginning thirty (30) days from the effective date of Coach’s termination without Cause. The payment of liquidated damages as set forth in this subsection is subject to the duty to mitigate in subsection 19.3 below.
Sample 1
AutoNDA by SimpleDocs
By ICAA. In its sole discretion, ICAA has the right to terminate this Agreement at any time during the Term without Cause. In the event ICAA terminates this Agreement without Cause, ICAA’s sole obligation shall be to pay Coach, as liquidated damages and not as a penalty, seventy-five percent (75%) of the amount equal to the remaining balance of Coach’s Guaranteed and Other Compensation that would have been owed to Coach if Coach was fully performing Coach’s duties through the end of the Term (the “ICAA Separation Payment”). The applicable sum due to Coach shall be paid by ICAA over twelve (12) months in equal installments beginning thirty (30) days from the effective date of Coach’s termination without Cause. The payment of liquidated damages as set forth in this subsection is subject to the duty to mitigate in subsection 21.3 below.
Sample 1
By ICAA. In its sole discretion, ICAA has the right to terminate this Agreement at any time during the Term without Cause. In the event ICAA terminates this Agreement without Cause, ICAA’s sole obligation shall be to pay Coach: (a) any Guaranteed Compensation, Other Compensation, Retention Bonus, and Performance Incentives earned as of the effective date of termination; and (b) as liquidated damages and not as a penalty, the amounts set forth below (the “ICAA Separation Payments”). The applicable sum due to Coach shall be paid by ICAA in equal monthly installment payments commencing within 30 days of the date of termination and continuing thereafter until the end of the month coinciding with the end of the Term.
Sample 1

Related to By ICAA

  • Trials The Ship shall run the following test and trials:

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Public Posting of Approved Users’ Research Use Statement The PI agrees that information about themselves and the approved research use will be posted publicly on the dbGaP website. The information includes the PI’s name and Requester, project name, Research Use Statement, and a Non-Technical Summary of the Research Use Statement. In addition, and if applicable, this information may include the Cloud Computing Use Statement and name of the CSP or PCS. Citations of publications resulting from the use of controlled-access datasets obtained through this DAR may also be posted on the dbGaP website.

  • By Client Client agrees to indemnify, defend and hold Agency, its officers, directors, employees, agents, attorneys, subsidiaries, affiliated companies, parent companies, representatives, and successors and assigns, harmless from and against all Losses to the extent such Losses arise out of or are primarily related to (i) the negligent or wrongful acts, errors, or omissions of Client or its employees, agents affiliates, assigns or any creditor or prior account holder, or the employees or agents of any of them, in connection with this Agreement, including but not limited to errors or omissions in connection with information furnished by Client to Agency concerning a Referred Account, or (ii) any collection effort by Client or any other collection agency as to a Referred Account.

  • By Either Party Either party may terminate this Agreement for convenience at any time effective after the first (1st) anniversary of the Installation Date by providing ninety (90) days' prior written notice to the other party at any time thereafter.

  • By Licensee Except for claims for which Oracle is obligated to indemnify Licensee under Section 7.2, Licensee shall defend, at Licensee's expense, any and all claims brought against Oracle, and shall pay all damages awarded by a court of competent jurisdiction, or such settlement amount negotiated by Licensee, arising out of or in connection with Licensee's reproduction, development or distribution of product(s) developed using the TCK. Licensee's obligation to provide a defense under this Section 7.5 shall arise provided that Oracle: (a) provides notice of the claim promptly to Licensee; (b) gives Licensee sole control of the defense and settlement of the claim; (c) provides to Licensee, at Licensee's expense, all available information, assistance and authority to defend; and (d) has not compromised or settled such proceeding without Licensee's prior written consent.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Procurement of Recovered Materials (1) In the performance of this contract, the Contractor shall make maximum use of products containing recovered materials that are EPA-designated items unless the product cannot be acquired

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

Time is Money Join Law Insider Premium to draft better contracts faster.